Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 3:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 268 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: methylphenidate HCl (Concerta) Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate

NCT00593112
View directory record Official record
Conditions
ADHD
Interventions
OROS methylphenidate, No intervention
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Sep 10, 2026, 3:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Diagnostic Utility of Attention Deficit Hyperactivity Disorder (ADHD) by Brain Activity Flow Patterns Analysis Using Evoked Response Potentials

NCT01063153
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Osmotic Release Methylphenidate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Sep 10, 2026, 3:35 AM EDT
Completed Phase 4 Interventional Results available

Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study

NCT02255565
View directory record Official record
Conditions
ADHD, Autism
Interventions
Very Low Dose Quillivant XR, Low Dose Quillivant XR, Moderate Dose Quillivant XR
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
5 Years to 16 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 10, 2026, 3:35 AM EDT
Completed No phase listed Observational

A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan

NCT04113551
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO), Guanfacine (GFC)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
17,418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 10, 2026, 3:35 AM EDT
Completed Not applicable Interventional Results available

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

NCT00129467
View directory record Official record
Conditions
Depression, Palliative Care, Cancer, Mental Disorder
Interventions
Methylphenidate, Placebo, Selective Serotonin Uptake Inhibitor (SSRI)
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 10, 2026, 3:35 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Severe Childhood Aggression (The TOSCA Study)

NCT00796302
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate HCl, Risperidone, Parent Management Training (PMT), Placebo
Drug · Behavioral
Lead sponsor
Michael Aman
Other
Eligibility
6 Years to 12 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Stony Brook, New York • Cleveland, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 10, 2026, 3:35 AM EDT
Not listed Phase 3 Interventional

A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV

NCT01599975
View directory record Official record
Conditions
HIV Dementia
Interventions
Long acting methylphenidate, Matched placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Sep 10, 2026, 3:35 AM EDT
Completed No phase listed Observational

Genetic Measurements in Blood Cells of Children Taking Adderall or Methylphenidate

NCT00341029
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
6 Years to 12 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 10, 2026, 3:35 AM EDT
Completed Phase 3 Interventional Results available

NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01835548
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
NT0102, Placebo
Drug
Lead sponsor
Neos Therapeutics, Inc
Industry
Eligibility
6 Years to 12 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Bradenton, Florida • Maitland, Florida • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 10, 2026, 3:35 AM EDT
Withdrawn Phase 4 Interventional

Adaptive Response to Intervention (RTI) for Students With ADHD

NCT03511976
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Tier 1 Classroom Management, Daily Report Card (DRC), Enhanced DRC (DRC-E), Stimulant
Behavioral · Drug
Lead sponsor
Florida International University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Miami, Florida • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 10, 2026, 3:35 AM EDT
Completed Phase 3 Interventional Results available

KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD

NCT03460652
View directory record Official record
Conditions
ADHD
Interventions
KP415 oral capsule
Drug
Lead sponsor
Zevra Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
19
States / cities
Little Rock, Arkansas • Colorado Springs, Colorado • Bradenton, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2021 · Synced Sep 10, 2026, 3:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CTx-1301 Comparative Bioavailability Study

NCT04138498
View directory record Official record
Conditions
ADHD
Interventions
Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release, Dexmethylphenidate 50 mg Tablet
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Sep 10, 2026, 3:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body

NCT07314333
View directory record Official record
Conditions
ADHD
Interventions
Centanafadine, Methylphenidate, Lisdexamfetamine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 10, 2026, 3:35 AM EDT
Completed Phase 3 Interventional Results available

NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT01654250
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
NWP09, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 12 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
9
States / cities
Little Rock, Arkansas • Huntington Beach, California • Irvine, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 10, 2026, 3:35 AM EDT
Enrolling by invitation Phase 4 Interventional

Precision Care for Major Depressive Disorder

NCT06580041
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Depressive Disorder, Major
Interventions
Pramipexole, Methylphenidate, Phenelzine, Mindfulness-based Stress Sensitivity Therapy (MBSST), Complicated Grief Treatment (CGT), Care as usual (CAU) plan
Drug · Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 10, 2026, 3:35 AM EDT
Recruiting Phase 4 Interventional

An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

NCT06577779
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Methylphenidate Hydrochloride Extended Release Capsule
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 10, 2026, 3:35 AM EDT
Completed Phase 4 Interventional

Concerta Treatment in Adults With ADHD NOS

NCT00181740
View directory record Official record
Conditions
ADHD NOS
Interventions
atomoxetine (Strattera)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2010 · Synced Sep 10, 2026, 3:35 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

NCT01552915
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
79
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 10, 2026, 3:35 AM EDT
Terminated Phase 3 Interventional

Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors

NCT00031798
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Depression, Fatigue, Quality of Life
Interventions
methylphenidate hydrochloride, quality-of-life assessment, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
7
States / cities
Phoenix, Arizona • Decatur, Illinois • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Sep 10, 2026, 3:35 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety

NCT02021214
View directory record Official record
Conditions
PTSD
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Sep 10, 2026, 3:35 AM EDT
Completed Phase 3 Interventional Results available

Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting

NCT01269463
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
Methylphenidate Hydrochloride Extended Release Capsule, Placebo
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
6 Years to 12 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 10, 2026, 3:35 AM EDT
Not listed Phase 4 Interventional

A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD

NCT02677519
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Aptensio XR
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
4 Years to 6 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Las Vegas, Nevada • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 10, 2026, 3:35 AM EDT
Recruiting Phase 4 Interventional

Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD

NCT04781972
View directory record Official record
Conditions
ADHD - Combined Type
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 10, 2026, 3:35 AM EDT
Completed Phase 3 Interventional

Further Studies of Attention Deficit Disorder - Residual Type (RT)

NCT00693212
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
methylphenidate, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
21 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1986 – 1994
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 5, 2008 · Synced Sep 10, 2026, 3:35 AM EDT